Lecturer Life Sciences: HU University of Applied Sciences | PhD in Neuroscience | Exotic animal keeper | Dancer | Runner | Tries to play guitar • He/Him ⬛🌫️⬜🟪
Joined November 2019
- Tweets760
- Following189
- Followers166
- Likes658
Back at the @ISLCPAIS , bit too late because of traffic issues. First talk is on the creation, goals and aims of the ilsc-PAIS working group
Time for the last talk by @DavidPutrino. But first some explanations about award tht are in the works by ILSC-PAIS. Proposal request will open somewhere in October.
Q: from Q fever advocacy - is there a way of measuring effects of Mito related symptoms? - no, not conventional. But putrino measures resting metabolic rate. Seems people with Mito dysfunction have higher BMR, through burning carbs
Takeaways:
1: treat drivers, not symptoms
2: complexity isn't mysterious
3: run towards complexity, not away from it.
For me this all boils down to wicked problems, interdisciplinary approaches and daring to take steps into the unknown. Hope the @ISLCPAIS makes that happen!
What do we need next: testing for large arrays of autoantibody activity. We now only have set specific tests.
Interventions: IVIG, FcRn inhibitors - make these more available
Next big step: personalized medicine eg. CAR-T
Autoimmunity: study: expose human IgG from controls and LC to human brain tissue. Antibodies are reacting to human brain tissue. Injecting mice with the AABs from pwLC with pain as symptom showed pain.
Mitochondrial transplantation following optic crush injury - autologous from a healthy muscle. Could this be an avenue. David Putrino is exploring this
mitochondrial dysfunction: many papers that show that this is happening in LC. But trying things in patients is trial and error. Know what exactly is wrong in the Krebs cycle would be a nice next step. But probably very individual
We are not adequately evaluating what happens in our bodies after SARS-CoV-2 (regarding viral/bacterial reactivation)
Viral reactivation: sustained reactivation in pwLC is possible. Also bacterial reactivation, bartonella henselae. Think broad about viral persistence, what else has SARS-CoV-2 riled up?
What do we need next: subtyping with viral persistence as a basis. Medications that can penetrate immune privileged sites if the virus is still there. Intracellular targeting of SARS-COV-2
Learning from successes and failures. Eg. The LC-PAX trial. Ideas of why it failed can also help inform future research.
Mystery 2- exploration of LC along 10 key symptoms
1: viral persistence. Lots of evidence for virus in some way sticking around. Eg antigen persistence in people with LC more frequent.
Mystery 1: we don't know how to diagnose LC
Mystery 2: we don't know why they are so sick
Mystery 3: we don't know how to treat LC
Time of the last parallel session at @ISLCPAIS. First on the PIPASC study on neuroinflammation after SARS-CoV-2 infection.